# Renasant Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/renasant-bio

- Industry: Biotechnology
- Headquarters: Berkeley, US
- Website: www.renasantbio.com
- Total disclosed funding: $30M
- Latest round: Seed (Jun 3, 2025)
- Investors on record: 4

## About

Renasant Bio, based in the US, is a biotech firm focused on developing innovative therapies for autosomal dominant polycystic kidney disease (ADPKD). The company harnesses advanced small molecule technologies to address critical kidney functions.Renasant Bio is dedicated to advancing treatments for autosomal dominant polycystic kidney disease (ADPKD). The company is headquartered in Berkeley, US. In July 2025, Renasant Bio raised USD 54.5 mn in Seed funding, co-led by 5AM Ventures, Atlas Venture, OrbiMed Advisors, and Qiming Venture Partners. The firm has had one total deal to date. The founder's background is not specified, and details about any predecessors or spin-off origins are not provided.Renasant Bio specializes in developing disease-modifying therapies for ADPKD through innovative small molecule correctors and potentiators. These products aim to restore the function of key renal proteins, polycystin 1 and 2 (PC1/2), essential for kidney regulation. By addressing genetic mutations linked to ADPKD, the therapies are designed to halt disease progression, reverse cyst growth, and enhance kidney function, targeting an estimated 12 million patients globally, including markets in North America, Europe, and parts of Asia.Renasant Bio’s revenue model hinges on the commercialization of its proprietary therapies aimed at ADPKD. The company partners with healthcare providers and pharmaceutical firms for streamlined access to its products. Revenue is generated as these therapies become available for prescriptions, focusing on oral small molecule formulations that improve patient adherence. The potential for long-term revenue growth is bolstered by the upcoming launch of first-in-class potentiator therapies, with an aim to create a sustainable financial framework that supports ongoing R&D while delivering innovative solutions to the market.In July 2025, Renasant Bio raised USD 54.5 mn in Seed funding to further advance its lead drug program, continue laboratory research, and develop new kidney disease treatments. The company plans to expand its reach into additional global markets, aiming to enhance access for patients affected by ADPKD. Recent funding will bolster these initiatives and support the rollout of new therapies scheduled for introduction in the coming years.

## Funding rounds

- Seed, Jun 3, 2025, $30M — Atlas Venture, OrbiMed Advisors, 5AM Ventures, Qiming Venture Partners

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Seed
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Seed
- Qiming Venture Partners (https://capitalatlas.ai/funds/qiming-venture-partners) — Seed